Online Education
- Home
- Online Education
Important Note
You will need to login first in order to enroll or view an activity. Login Here
*Note: ✔ = Contact Hours Provided AND ✖ = No Contact Hours Provided
Best Transition Practices for Adolescents and Young Adults with Sickle Cell Disease
- Credits: 0.5 (ACCME), 0.5 (ANCC)
- Expiration Date: July 8, 2022
Best Transition Practices for Adolescents and Young Adults with Sickle Cell Disease Details
Activity Number and Title
21HT50947 - Best Transition Practices for Adolescents and Young Adults with Sickle Cell Disease
Release Date
July 8, 2021
Expiration Date
5:00 PM Eastern, July 8, 2022
The estimated time to complete this activity is 30 minutes.
Purpose Statement
The purpose of this activity is to enable the learners to increase knowledge of the care needs of adolescents and young adults (AYAs), the emotional and social development of adolescence, the six core elements of a transition program, and the emotional/social milestones that should be addressed in a transition program for AYAs living with sickle cell disease (SCD).
Activity Description
This online learning activity is focused on improving health outcomes for adolescents and young adults (AYAs) with sickle cell disease (SCD) by improving transition programs and services available for these individuals. The activity will review the emotional and social development of adolescence. It will also discuss the health risks associated with transition among AYAs living with SCD. The module differentiates the pediatric and adult models of care, and examines the six core elements of transition programs, as derived from www.GotTransition.org. Finally, the activity will discuss the medical, social, and educational milestones that should be addressed in transition programs for AYAs with SCD.
Target Audience
This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, and other health care providers who treat adolescents and young adults with sickle cell disease and wish to improve outcomes associated with the transition from pediatric to adult care for these patients.
Educational Objectives
At the conclusion of this enduring material, the participants should be better able to:
- Review emotional and social development of adolescence
- Identify health risks associated with transition among adolescents and young adults (AYAs) living with sickle cell disease (SCD)
- Differentiate pediatric and adult models of sickle cell care
- Discuss the six core elements of a transition program
- Describe the medical, social, and educational milestones that should be addressed in a transition program for AYAs living with SCD
Faculty
- Emily Riehm Meier, MD, MSHS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid from 5/1/2021 to 5/2/2022. PAs should only claim credit commensurate with the extent of their participation. AAPA reference number: CME-202573.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Reducing Complications of Therapeutic Blood Transfusion in Sickle Cell Disease - Accredited
- Credits: CNE, CME
- Expiration Date: October 16, 2021
Reducing Complications of Therapeutic Blood Transfusion in Sickle Cell Disease - Accredited Details
Activity Title
Reducing Complications of Therapeutic Blood Transfusion in Sickle Cell Disease
- Introduction (WD2833)
- Module 1. Use of Transfusion During Acute Illness (WD2943)
- Module 2. Delayed Hemolytic Transfusion Reactions (WD2944)
- Module 3. Management of Chronic Transfusion (WD2945)
About the Activity
Transfusion is an established therapy in sickle cell disease. It can treat and prevent certain disease complications, reducing morbidity and mortality; but there are unique aspects of transfusing individuals with sickle cell disease that must be taken into consideration to maximize benefits and minimize complications. In 2014, the National Heart Lung and Blood Institute of the National Institutes of Health released an expert panel report on sickle cell disease management that includes evidence-based recommendations for transfusion and the avoidance and management of transfusion complications. In addition, guidelines from Great Britain were published in 2017 addressing laboratory and clinical management of transfusion in sickle cell disease. This course presents these and other important aspects of quality, effective care for individuals with sickle cell disease.
Purpose Statement
Activities are designed to increase knowledge and change competency of transfusion practices and strategies for individuals with hemoglobin disorders. Content is derived from actual peer-reviewed publications.
Educational Objectives
Introduction
- Describe the optimal hemoglobin level when transfusing a sickle cell patient
- List common reasons for transfusing individuals with sickle cell disease
- Recognize common complications of transfusion in sickle cell disease
- Locate current evidence-based recommendations for transfusion in sickle cell disease
Module 1. Use of Transfusion During Acute Illness (WD2943)
- Recognize indications for red blood cell transfusion during acute illness in individuals with sickle cell disease
- Describe appropriate selection of blood products for transfusion during acute illness in individuals with SCD
- Identify management strategies for acute splenic sequestration in SCD
- Describe indications for RBC transfusion prior to elective surgical procedures in SCD
Module 2. Delayed Hemolytic Transfusion Reactions (WD2944)
- Describe practice recommendations for transfusion in sickle cell disease patients with acute chest syndrome
- Explain the pathophysiology of delayed hemolytic transfusion reactions and hyperhemolysis
- List techniques for evaluating alloantibodies and DHTR
- Explain the assessment and management of DHTR
Module 3. Management of Chronic Transfusion (WD2945)
- Describe the role of chronic transfusion in preventing and managing certain complications of sickle cell disease
- Describe prevention and management of alloimmunization in individuals on chronic transfusion
- Describe the importance of iron overload in chronically transfused patients with sickle cell disease
- Describe the management of iron overload in patients on chronic transfusion
Target Audience
DOs, MDs, NPs, PAs
Faculty w/ credentials
Introduction
- James Eckman, M.D., Professor Emeritus of Hematology and Oncology, Emory University School of Medicine; Founding Director of the Comprehensive Sickle Cell Center at Grady Health System
Module 1. Use of Transfusion During Acute Illness (WD2943)
- Peter A. Lane, M.D., Professor of Pediatrics, Emory University School of Medicine; Director, Sickle Cell Disease Program, Children's Healthcare of Atlanta
Module 2. Delayed Hemolytic Transfusion Reactions (WD2944)
- Ross Fasano, MD, Assistant Professor in the Department of Laboratory Medicine, Emory University School of Medicine; Director of Apheresis and Pediatric Hematologist, Children's Healthcare of Atlanta
Module 3. Management of Chronic Transfusion (WD2945)
- James Eckman, MD, Professor Emeritus of Hematology and Oncology, Emory University School of Medicine; Founding Director of the Comprehensive Sickle Cell Center, Grady Health System
Important Dates
Origination Date: August 25, 2017
Renewal Date: October 16, 2019
Expiration Date: October 16, 2021
Unapproved Use Disclosure
Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
Non-endorsement of Products
CDC, our planners, content experts, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters. Planners have reviewed content to ensure there is no bias.
Method of Participation
There are no fees for participating in and receiving credit for this activity. In order to receive credit,
- Complete the Provider Training Video Series at Georgia Health Policy Center
- Complete the evaluation at CDC Training and Continuing Education Online
- Pass the posttest at 75% (minimum score) at CDC Training and Continuing Education Online
Joint Providership Statement
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Centers for Disease Control and Prevention and Georgia State University.
The Centers for Disease Control and Prevention, Emory University School of Medicine, and Georgia State University are jointly providing the CNE for this activity.
Accreditation Statement and Contact Hours
CME: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Centers for Disease Control and Prevention and Georgia State University. The Centers for Disease Control and Prevention is accredited (by the ACCME) to provide medical education for physicians. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE: The Centers for Disease Control and Prevention is accredited as a provider of Continuing Nursing Education (CNE) by the American Nurses Credentialing Center's Commission on Accreditation.
Please view individual training videos for information on accreditation and contact hours.
Financial Support
CDC did not accept commercial support for this continuing education activity.
Acknowledgment
Development of this course was supported by Cooperative Agreement DD14-1406, funded by the Centers for Disease Control and Prevention (CDC). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC or Department of Health and Human Services.
Contact Information
If you have any questions about this activity, please contact Mary Hulihan PhD, Health Scientist, Epidemiology and Surveillance Branch, Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, CDC, at 404-498-6724.
System Requirements
- Computer hardware
- Internet connection
- Browser
The Partners in Bleeding Disorders Education Program is supported by educational grants from Takeda Pharmaceuticals U.S.A, Inc.; Genentech, a member of the Roche Group; and the National Hemophilia Foundation (NHF).
Copyright © 2022 Indiana Hemophilia & Thrombosis Center. All rights reserved. Privacy Policy | Travel Policy | Terms of Service Credits